Thromb Haemost 1990; 64(01): 108-112
DOI: 10.1055/s-0038-1647263
Original Article
Schattauer GmbH Stuttgart

Azidothymidine (AZT) in the Treatment of Symptomatic HIV-1-Infected Hemophiliacs

S Eichinger
The First Department of Medicine, Division of Haematology and Blood Coagulation, Univeisity of Vienna, Vienna, Austria
,
I Pabinger
The First Department of Medicine, Division of Haematology and Blood Coagulation, Univeisity of Vienna, Vienna, Austria
,
H Hartl
The First Department of Medicine, Division of Haematology and Blood Coagulation, Univeisity of Vienna, Vienna, Austria
,
C Stain
The First Department of Medicine, Division of Haematology and Blood Coagulation, Univeisity of Vienna, Vienna, Austria
,
S Mayerhofer
1   The First Department of Dermatology, Univeisity of Vienna, Vienna, Austria
,
C Schweiger
2   The Department of Clinical Chemistry, Univeisity of Vienna, Vienna, Austria
,
P Kier
The First Department of Medicine, Division of Haematology and Blood Coagulation, Univeisity of Vienna, Vienna, Austria
,
I Schwarzinger
The First Department of Medicine, Division of Haematology and Blood Coagulation, Univeisity of Vienna, Vienna, Austria
,
P A Kyrle
The First Department of Medicine, Division of Haematology and Blood Coagulation, Univeisity of Vienna, Vienna, Austria
,
K Lechner
The First Department of Medicine, Division of Haematology and Blood Coagulation, Univeisity of Vienna, Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received 07 December 1989

Accepted after revision 28 February 1990

Publication Date:
25 July 2018 (online)

Summary

Twenty-one immunodeficiency virus 1 (HIV 1)-positive hemophilic patients were treated with Azidothymidine (AZT) for symptomatic HIV infection. The median observation period was 20.5 months.

At 25 months the probability of survival was 82%, the probability of progression of disease from CDC III or IV C2 to IV C1 (AIDS) was 20% in patients on continuous AZT treatment and 50% in patients with intermption of treatment. Three patients developed severe leukopenia and 3 patients severe anemii during AZT treatment. In 1 patient a dose-dependent striking increase of transaminases during AZT treatment was observed. In 7 patients treatment was intermpted, in 1 patient because of anemia, in 1 because of pruritus and in 5 patients because of noncompliance.

No signiticant changes in the consumption of clotting factor concentrates and number of bleeding episodes before and during AZT treatment were noted.

We conclude, that both hematological and non-hematological side effects of AZT in HIV 1-infected hemophilic patientr ur. comparable to those seen in other risk groups . AzT does not increase the bleeding tendency in this patient group.

 
  • References

  • 1 Ragni MV, Winkelstein A, Kingsley L, Spero JA, Lewis JH. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence and immunologic correlates of HIV infection in patients with hemophilia A and B. Blood 1987; 70: 786-790
  • 2 Stain C, Pabinger-Fasching I, Guggenberger K, Koller U, Stain M, Hard H, Heinz F, Mayerhofer S, Kyrle PA, Lechner K, Korninger C. High risk of acquired immunodeficiency syndrome (AIDS) and of AIDS related complex (ARC) in haemophiliacs seropositive for more than 5 years. Thromb Haemostas 1989; 61 (03) 354-356
  • 3 Goedert J, Kessler C, Aledort L, Biggar R, Andes WA, White G II, Drummond J, Vaidya K, Mann D, Eyster E, Ragni M, Lederman M, Cohen A, Bray G, Rosenberg P, Friedman R, Hilgartner M, Blattner W, Kroner B, Gail M. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321: 1141-1148
  • 4 Fischl M, Richman D, Grieco M, Gottlieb M, Volberding P, Laskin O, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D. and the AZT collaborative working group. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-191
  • 5 Richman D, Fischl M, Grieco M, Gottlieb M, Volberding P, Laskin O, Leedom J, Groopman J, Mildvan D, Hirsch M, Jackson G, Durack D, Nusinoff-Lehrman S. and the AZT collaborative working group. The toxicity of Azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo controlled trial. N Engl J Med 1987; 317: 192-197
  • 6 Pottage J, Benson C, Spear J, Landay A, Kessler H. Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine. JAMA Nov 25 1988 260. 02
  • 7 Surbone A, Yarchoan R, McAtee N, Blum R, Maha M, Allain JP, Thomas R, Mitsuya H, Nusinoff-Lehrman S, Leuther M, Pluda J, Jacobsen F, Kessler H, Myers Ch, Broder S. Treatment of the acquired syndrome (AIDS) and AIDS-related complex with a regime of 3’-Azido-2’, 3’-dideoxythymidine (Azidothymidine or Zidovudine) and Acyclovir. Ann Intern Med 1988; 108: 534-540
  • 8 Doumon E, Rozenbaum W, Michon C, Perrone C, De Truchis P, Bouvet E, Levacher M, Matheron S, Gharakhanian S, Girard PM, Salmon D, Leport C, Dazza MC, Regnier B. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet December 3 1988; 1297-1302
  • 9 Creagh-Kirk DoiP, Andrews E, Nusinoff-Lehrman S, Tilson H, Hoth D, Barra D. Survival experiences among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA 1988; 260: 3009-3015
  • 10 Ranki A, Mattinen S, Yarchoan R, Broder S, Ghrayeb J, Lahdevirta J, Krohn K. T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. AIDS 1989; 3: 63-69
  • 11 Ragni MV, Tama G, Lewis JH, Ho M. Increased frequency of haemarthroses in haemophilic patients treated with zidovudine. Lancet June 25 1988; 1454-1455
  • 12 Schimpf KL, Zimmermann K, Rudel J, Thanner G, Zeltsch P. Results of liver biopsies, rate of icteric hepatitis and frequency of anti-Hbs and Hbs-antigen in patients of the Heidelberg hemophilia center. Thromb Haemostas 1977; 38: 340 (Abstr).
  • 13 Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3’-Azido-2’,3’-dideoxythymidine (Zidovudine) and related dideoxynucleosides. N Engl J Med 1989; 321: 726-738
  • 14 Centers for Disease Control, U.S. Department of Health and Human Services. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections. Ann Intern Med 1986; 105: 234-237
  • 15 Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987 36. No IS
  • 16 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
  • 17 Wilcoxon F. Individual comparison by ranking methods. Biometrics Bull 1945; 1: 80
  • 18 Schramm W, Roggendorf M, Rommel F, Kammerer R, Pohlmann H, Raßhofer R, Gürtler L, Deinhardt F. Prevalence of antibodies to hepatitis C virus (HCV) in haemophiliacs. Blut 1989; 59: 390-392
  • 19 Dubin G, Braffman M. Zidovudine-induced hepatotoxicity. Ann Intern Med 1989; 110: 85-86